GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HUTCHMED (China) Ltd (NAS:HCM) » Definitions » EV-to-Revenue

HUTCHMED (China) (HUTCHMED (China)) EV-to-Revenue

: 2.48 (As of Today)
View and export this data going back to 2016. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, HUTCHMED (China)'s enterprise value is $2,080.6 Mil. HUTCHMED (China)'s Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $838.0 Mil. Therefore, HUTCHMED (China)'s EV-to-Revenue for today is 2.48.

The historical rank and industry rank for HUTCHMED (China)'s EV-to-Revenue or its related term are showing as below:

HCM' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.59   Med: 13.96   Max: 28.92
Current: 2.48

During the past 13 years, the highest EV-to-Revenue of HUTCHMED (China) was 28.92. The lowest was 1.59. And the median was 13.96.

HCM's EV-to-Revenue is ranked worse than
53.76% of 1025 companies
in the Drug Manufacturers industry
Industry Median: 2.33 vs HCM: 2.48

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-19), HUTCHMED (China)'s stock price is $16.52. HUTCHMED (China)'s Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $4.82. Therefore, HUTCHMED (China)'s PS Ratio for today is 3.42.


HUTCHMED (China) EV-to-Revenue Historical Data

The historical data trend for HUTCHMED (China)'s EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HUTCHMED (China) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.43 18.12 14.35 5.02 2.71

HUTCHMED (China) Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.35 - 5.02 - 2.71

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HUTCHMED (China) EV-to-Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where HUTCHMED (China)'s EV-to-Revenue falls into.



HUTCHMED (China) EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

HUTCHMED (China)'s EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=2080.594/837.999
=2.48

HUTCHMED (China)'s current Enterprise Value is $2,080.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HUTCHMED (China)'s Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $838.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HUTCHMED (China)  (NAS:HCM) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

HUTCHMED (China)'s PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=16.52/4.824
=3.42

HUTCHMED (China)'s share price for today is $16.52.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was $4.82.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HUTCHMED (China) EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of HUTCHMED (China)'s EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


HUTCHMED (China) (HUTCHMED (China)) Business Description

Traded in Other Exchanges
Address
2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

HUTCHMED (China) (HUTCHMED (China)) Headlines